GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Artificial Intelligence /AI ML-based nomogram for mortality risk stratification in cirrhotic patients

AI ML-based nomogram for mortality risk stratification in cirrhotic patients

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated November 1, 2025

Quick Answer

The AI/ML-based nomogram developed in this study serves as a predictive tool for estimating in-hospital mortality risk among cirrhotic patients with sepsis. This retrospective single-center study analyzed data from 264 patients admitted between January 2018 and July 2025, dividing them into Survivor and Non-survivor groups, with 28.


The AI/ML-based nomogram developed in this study serves as a predictive tool for estimating in-hospital mortality risk among cirrhotic patients with sepsis. This retrospective single-center study analyzed data from 264 patients admitted between January 2018 and July 2025, dividing them into Survivor and Non-survivor groups, with 28.4% succumbing to the condition during hospitalization. To ensure robust model performance, the dataset was split into a training set (70%) and validation set (30%).

Key predictors of mortality identified included alcoholic cirrhosis, Child-Pugh score, mechanical ventilation, total bilirubin (TBiL), and heart rate (HR). These factors were selected using LASSO regression and further optimized with multivariate logistic regression. A nomogram was constructed to visually quantify individual mortality risks based on the weighted contribution of these predictors. The model demonstrated excellent discrimination with an AUC of 0.81 in the training set and 0.83 in the validation set, while calibration plots showed strong agreement between predicted and observed outcomes.

Alcoholic cirrhosis was a significant risk factor, with a 3.7 times higher mortality rate compared to non-alcoholic cases. Higher Child-Pugh scores indicated worsening prognosis, mechanical ventilation doubled mortality risk, and elevated TBiL levels reflected impaired hepatic function. Extreme heart rate abnormalities also correlated with poor outcomes. Infection complications like spontaneous bacterial peritonitis and esophageal variceal bleeding were more frequent among non-survivors.

The nomogram provides clinicians with a quantitative tool for mortality risk stratification, enabling early intervention strategies. Its findings align with global trends in cirrhosis-related mortality, emphasizing its clinical relevance and utility in managing high-risk patients effectively.

Related Q&A

AI and U.S. Healthcare Costs: NEJM Catalyst | July 2026

Introduction: Artificial intelligence is rapidly transforming healthcare through drug discovery, clinical decision support, remote monitoring, and administrative automation. While AI is widely expected to reduce healthcare costs, this perspective argues that current payment models and...

Large AI Models and Healthcare: Nature Medicine | June 2026

Introduction: Large frontier AI models such as GPT-5 and Gemini have achieved impressive results across numerous healthcare benchmarks. However, high benchmark scores alone may not reflect real-world clinical reliability. This study systematically evaluated the robustness...

AI Ethics From Silicon Valley to the Vatican: JAMA | July 2026

Introduction: Artificial intelligence is rapidly transforming medicine, but its influence extends far beyond healthcare. This JAMA AI Conversations article explores how AI ethics has become a global societal issue, engaging technology leaders, policymakers, healthcare professionals,...

Physician-Complementing AI in Oncology: The ASCO Post | June 2026

Introduction: Artificial intelligence is rapidly transforming oncology, evolving from image interpretation and pathology analysis to supporting complex clinical decision-making. This perspective argues that AI should enhance the capabilities of oncologists rather than replace their expertise....

AI-Based Clinical Trial End Points: A New Era in Drug Development: NEJM AI | July 2026

Introduction Clinical trial endpoints have traditionally relied on expert human interpretation, particularly for pathology-based outcomes. However, variability between observers, cost, and time remain important limitations. This NEJM AI perspective discusses how artificial intelligence is beginning...

Medical AI Assistant: Publication or Medical Device?: NEJM AI | July 2026

Introduction: As artificial intelligence becomes increasingly integrated into clinical practice, an important question arises: should AI assistants be regulated as medical devices or viewed as evidence-based clinical methodologies? This NEJM AI perspective proposes a new...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer